Floatz logo

5-azacytidine

Platinum Resistant Ovarian Cancer

M.D. Anderson Cancer CenterPhase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Platinum Resistant Ovarian Cancer cohort.

Asset / SponsorPhaseRating
COMBRESTATIN A4
Mateon Therapeutics
Phase 2/3B
Upifitamab Rilsodotin
Mersana Therapeutics
Phase 1/2CCC
Losartan
Massachusetts General Hospital
Phase 2CCC
Utidelone
Fudan University
Phase 2CCC
Fruquintinib
Fudan University
Phase 2CCC
Rucaparib
Ohio State University Comprehensive Cancer Center
Phase 1CC
Hwk-016, Mucin-16-Targeted Adc
Whitehawk Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →